Do AMH and FSHB genetic variants influence ovarian reserve, FSH signaling, and menopause timing?

Genetic research demonstrates that variations in the AMH and FSHB genes significantly influence the reproductive lifespan and the hormonal environment. These genes are central to the regulation of follicle development and the depletion of the ovarian reserve, which directly determine the timing of menopause and the associated decline in ovarian steroids.

Genetic impact on ovarian reserve and signaling

Evidence confirms that genetic polymorphisms in the FSHB and AMH pathways modulate the endocrine signaling required for follicular growth and maintenance.

• FSHB rs10835638 (c.-211G>T): This variant in the promoter region of the follicle-stimulating hormone beta subunit reduces transcriptional activity. The "T" allele is associated with lower circulating FSH levels (explaining 2.3–4.65% of the variance in levels), which leads to slower follicle recruitment and delayed ovarian aging.
• AMH rs10407022: Variants in the Anti-Müllerian Hormone gene correlate with differences in serum AMH levels—a key biomarker for the primordial follicle pool. The TT genotype has been linked to significantly lower AMH concentrations (mean differences of ~1.41 ng/mL in certain cohorts) and an increased risk of primary ovarian insufficiency.

Association with age at natural menopause (ANM)

Large-scale genome-wide association studies (GWAS) have established these loci as robust predictors of menopause timing.

• Menopause Delay: The FSHB rs10835638 T-allele, by lowering FSH, is associated with longer menstrual cycles and an increase in the age at menopause by approximately 0.13 to 0.3 years per allele.
• Follicular Depletion: There is a strong genetic correlation (rg = 0.82) between circulating AMH levels and the age at natural menopause. Variants that accelerate the depletion of the follicular reserve inevitably shift the onset of menopause earlier.

Mechanistic basis for steroid decline

While direct longitudinal data on the "steepness" of hormone drops are limited, the association between these variants and menopause timing makes an earlier or more pronounced steroid decline mechanistically plausible.

• Steroidogenic Pathways: Since FSH is the primary driver of estradiol production, variants that alter FSH levels or sensitivity (like FSHB and FSHR) modify the reproductive timeline. An earlier age at menopause necessarily results in an earlier cessation of estradiol and progesterone production.
• Transition Dynamics: Variants that influence the rate of follicle depletion may influence how abruptly hormone levels fluctuate during the perimenopausal transition, though specific "slope" metrics for steroid decline remain an emerging area of study.

Bottom line

Genetic variants in AMH and FSHB are scientifically supported drivers of ovarian reserve capacity and menopause timing. By altering FSH signaling and follicle depletion rates, these variants plausibly determine when a woman experiences the significant decline in ovarian steroids associated with the menopausal transition.